Latest Ratios: P/E Ratio 17.2x · EV/EBITDA 10.6x · ROE 21.6%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26.8B | $15.4B | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $44.2B | $116.0B | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | 17.18 | 1.39 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.41 | 0.03 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.43 | 0.29 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | 3.73 | — | — | — | — | — | — | — | — | — |
| P/OCF | 10.04 | 0.99 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.25 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 10.58 | 3.29 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 11.32 | 4.92 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 28.10 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.8% | 12.8% | 15.1% | 10.9% | 15.9% | 18.9% | 16.7% | 15.6% | 14.5% | 14.6% | 12.5% |
| Operating Margin | 4.8% | 4.8% | 5.7% | 1.5% | 6.6% | 9.2% | 7.6% | 6.6% | 3.9% | 4.1% | 3.9% |
| Net Profit Margin | 2.4% | 2.4% | 2.3% | -0.3% | 4.1% | 5.9% | 1.7% | 3.0% | 0.0% | 0.3% | 0.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.6% | 21.6% | 19.8% | -2.2% | 32.5% | 46.5% | 12.1% | 20.1% | 0.1% | 2.2% | 0.9% |
| ROA | 4.4% | 4.4% | 4.2% | -0.5% | 7.6% | 11.4% | 3.2% | 5.0% | 0.0% | 0.5% | 0.2% |
| ROIC | 11.2% | 11.2% | 12.5% | 2.9% | 14.1% | 22.1% | 17.0% | 12.7% | 7.3% | 7.1% | 6.7% |
| ROCE | 12.4% | 12.4% | 14.1% | 3.4% | 16.8% | 24.7% | 18.5% | 14.1% | 8.3% | 9.0% | 8.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.40 | 2.40 | 2.68 | 2.35 | 2.10 | 2.17 | 1.70 | 1.84 | 2.04 | 2.18 | 2.39 |
| Debt / EBITDA | 3.57 | 3.57 | 3.78 | 7.04 | 2.95 | 2.44 | 2.62 | 3.02 | 4.77 | 5.09 | 5.08 |
| Net Debt / Equity | — | 1.92 | 1.99 | 1.88 | 1.83 | 1.68 | 1.25 | 1.53 | 1.72 | 1.73 | 1.99 |
| Net Debt / EBITDA | 2.85 | 2.85 | 2.80 | 5.63 | 2.58 | 1.90 | 1.92 | 2.52 | 4.02 | 4.04 | 4.23 |
| Debt / FCF | — | 24.37 | 6.47 | 22.02 | 43.30 | 6.78 | 3.06 | 5.22 | 10.43 | 21.65 | 250.62 |
| Interest Coverage | 2.57 | 2.57 | 15.60 | 3.44 | 19.28 | 34.51 | 5.65 | 3.24 | 2.01 | 1.49 | 2.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.60 | 1.60 | 1.47 | 1.64 | 1.44 | 1.40 | 1.48 | 1.47 | 1.71 | 1.24 | 1.02 |
| Quick Ratio | 0.91 | 0.91 | 0.90 | 0.95 | 0.75 | 0.84 | 0.93 | 0.86 | 1.04 | 0.81 | 0.65 |
| Cash Ratio | 0.41 | 0.41 | 0.48 | 0.46 | 0.24 | 0.39 | 0.48 | 0.35 | 0.41 | 0.40 | 0.28 |
| Asset Turnover | — | 1.90 | 1.65 | 1.76 | 1.85 | 1.75 | 1.65 | 1.62 | 1.59 | 1.50 | 1.66 |
| Inventory Turnover | 9.42 | 9.42 | 8.63 | 9.83 | 8.53 | 8.66 | 9.91 | 9.95 | 10.71 | 11.19 | 12.14 |
| Days Sales Outstanding | — | 22.78 | 20.25 | 16.47 | 19.24 | 20.01 | 18.91 | 19.87 | 19.40 | 20.88 | 20.54 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 11.8% | 57.2% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 79.4% | 79.4% | 46.1% | — | 28.0% | 34.8% | 31.3% | 0.1% | 503.5% | 17.5% | 471.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.8% | 72.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | 26.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 2.1% | 20.7% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 13.8% | 77.9% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1.1B | $2.2B | $2.2B | $2.3B | $2.5B | $2.7B | $2.7B | $2.7B | $2.8B | $2.7B |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JBS stock.
Jbs N.V.'s current P/E ratio is 17.2x. The historical average is 1.4x. This places it at the 100th percentile of its historical range.
Jbs N.V.'s current EV/EBITDA is 10.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.3x.
Jbs N.V.'s return on equity (ROE) is 21.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 14.8%.
Based on historical data, Jbs N.V. is trading at a P/E of 17.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Jbs N.V.'s current dividend yield is 11.76% with a payout ratio of 79.4%.
Jbs N.V. has 12.8% gross margin and 4.8% operating margin.
Jbs N.V.'s Debt/EBITDA ratio is 3.6x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Leverage amid thin margins
Metrics are mathematically derived from official filings.
Low Multiples Reflect Governance and Leverage Discount
Based on reported figures, JBS trades at a trailing P/E of 17.18 and EV/EBITDA of 10.58, which sit well below Hormel's 36.31 P/E and 17.28 EV/EBITDA, suggesting the market applies a meaningful discount to its earnings stream.
The forward P/E of 3.25 implies that the market expects a sharp earnings recovery or is pricing in a very different profit outlook than the trailing figures indicate, and this gap warrants caution. The PEG of 0.40 would appear attractive only if growth estimates are reliable, which is doubtful given the volatile EPS history. The discount relative to US-domiciled peers likely reflects governance concerns, Brazil-related risk premia, and a 2.78 debt-to-equity ratio, so investors should monitor whether the apparent cheapness persists once earnings normalize.
Margin Compression Erodes Earnings Power
According to recent SEC filings, JBS's gross margin fell from 16.5% in 2024Q3 to roughly 10.6% in 2026Q3, while operating margin compressed from 7.8% to 2.3%, indicating that cost pressure is outpacing revenue growth.
The gap between a 10.6% gross margin and a 2.3% operating margin implies that SG&A and other operating costs consume most of the gross profit, leaving little cushion against input cost swings. Net margin of 0.7% in 2026Q3 and negative in 2026Q2 suggests earnings power is currently weak on a reported basis. Adjusting for biological asset fair-value effects and non-recurring items could change the picture, and that adjustment warrants further investigation before relying on headline margins.
Returns Decaying From Earlier Peak Levels
As reported in financial statements, JBS's ROIC declined from 4.4% in 2024Q3 to 2.1% in 2026Q3, while ROE fell from 7.5% to 3.0%, pointing to a sustained erosion in returns on the capital base.
The drop in ROIC tracks the compression in operating margin more closely than any change in capital turnover, suggesting the decline is margin-driven rather than efficiency-driven. Returns at this level sit close to the company's cost of capital given its heavy debt load, which raises the question of whether recent acquisitions are generating adequate economic value. Investors should monitor whether returns recover toward prior levels or continue to decay.
Debt Load Outpacing Earnings Coverage
Based on JBS's reported figures, debt-to-equity climbed from 2.30 in 2024Q3 to 2.78 in 2026Q3, while debt-to-EBITDA reached 21.64 in the latest quarter, suggesting debt service is becoming harder to cover from current earnings.
Interest coverage swung between 0.73 and 14.39 over the period, and the most recent readings of 1.43 leave little margin for error if operating profit falls further. The combination of rising leverage and thin operating income implies reduced financial flexibility, and change-of-control provisions flagged in risk disclosures add refinancing sensitivity. The trajectory warrants monitoring of debt reduction progress and refinancing terms.
Low Forward Multiple May Mislead Valuation
The P/E ratio is most commonly misapplied to JBS, since reported earnings swing from positive to negative across recent quarters, making a single-period P/E an unreliable anchor for a commodity processor with biological asset valuation effects.
A low P/E can appear to signal value, but when earnings are depressed by commodity cycles and non-cash fair-value adjustments, the ratio may understate the true cost of the equity claim. EV/EBITDA is similarly distorted by leverage and by biological asset accounting, so normalized free cash flow yield or through-cycle margin analysis would give a more reliable read. Investors should treat the apparent cheapness as a hypothesis to test rather than a conclusion.